Solanezumab

Solanezumab is a medication developed to treat Alzheimer's disease. It works by targeting and binding to amyloid-beta proteins in the brain, which form harmful plaques that are believed to contribute to the progression of Alzheimer's. By preventing these proteins from accumulating, Solanezumab aims to slow down cognitive decline and improve memory function in patients. While studies have shown some promise in mild cases of the disease, ongoing research is needed to fully understand its effectiveness and potential benefits for those affected by Alzheimer's.